Savela Emily S, Winnett Alexander, Romano Anna E, Porter Michael K, Shelby Natasha, Akana Reid, Ji Jenny, Cooper Matthew M, Schlenker Noah W, Reyes Jessica A, Carter Alyssa M, Barlow Jacob T, Tognazzini Colten, Feaster Matthew, Goh Ying-Ying, Ismagilov Rustem F
California Institute of Technology, 1200 E. California Blvd., Pasadena, CA, USA 91125.
City of Pasadena Public Health Department, 1845 N. Fair Oaks Ave., Pasadena, CA, USA 91103.
medRxiv. 2021 Aug 26:2021.04.02.21254771. doi: 10.1101/2021.04.02.21254771.
Early detection of SARS-CoV-2 infection is critical to reduce asymptomatic and pre-symptomatic transmission, curb the spread of variants by travelers, and maximize treatment efficacy. Low-sensitivity nasal-swab testing (antigen and some nucleic-acid-amplification tests) is commonly used for surveillance and symptomatic testing, but the ability of low-sensitivity nasal-swab tests to detect the earliest stages of infection has not been established. In this case-ascertained study, initially-SARS-CoV-2-negative household contacts of individuals diagnosed with COVID-19 prospectively self-collected paired anterior-nares nasal-swab and saliva samples twice daily for viral-load quantification by high-sensitivity RT-qPCR and digital-RT-PCR assays. We captured viral-load profiles from the incidence of infection for seven individuals and compared diagnostic sensitivities between respiratory sites. Among unvaccinated persons, high-sensitivity saliva testing detected infection up to 4.5 days before viral loads in nasal swabs reached the limit of detection of low-sensitivity nasal-swab tests. For most participants, nasal swabs reached higher peak viral loads than saliva, but were undetectable or at lower loads during the first few days of infection. High-sensitivity saliva testing was most reliable for earliest detection. Our study illustrates the value of acquiring early (within hours after a negative high-sensitivity test) viral-load profiles to guide the appropriate analytical sensitivity and respiratory site for detecting earliest infections. Such data are challenging to acquire but critical to design optimal testing strategies in the current pandemic and will be required for responding to future viral pandemics. As new variants and viruses emerge, up-to-date data on viral kinetics are necessary to adjust testing strategies for reliable early detection of infections.
早期检测严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染对于减少无症状和症状前传播、遏制旅行者传播变异株以及最大化治疗效果至关重要。低灵敏度的鼻拭子检测(抗原检测和一些核酸扩增检测)通常用于监测和有症状检测,但低灵敏度鼻拭子检测在检测感染最早阶段的能力尚未得到证实。在这项病例确诊研究中,确诊感染2019冠状病毒病(COVID-19)个体的最初SARS-CoV-2检测呈阴性的家庭接触者每天前瞻性地自行采集配对的前鼻孔鼻拭子和唾液样本两次,通过高灵敏度逆转录定量聚合酶链反应(RT-qPCR)和数字逆转录聚合酶链反应(digital-RT-PCR)检测进行病毒载量定量。我们获取了7名个体感染发病时的病毒载量谱,并比较了不同呼吸道部位的诊断灵敏度。在未接种疫苗的人群中,高灵敏度唾液检测在鼻拭子病毒载量达到低灵敏度鼻拭子检测的检测限之前4.5天就能检测到感染。对于大多数参与者来说,鼻拭子的病毒载量峰值高于唾液,但在感染的最初几天检测不到或病毒载量较低。高灵敏度唾液检测对于最早检测最为可靠。我们的研究说明了获取早期(在高灵敏度检测呈阴性后的数小时内)病毒载量谱对于指导检测最早感染的适当分析灵敏度和呼吸道部位的价值。此类数据获取具有挑战性,但对于设计当前大流行中的最佳检测策略至关重要,并且应对未来病毒大流行也将需要此类数据。随着新的变异株和病毒出现,关于病毒动力学的最新数据对于调整检测策略以可靠地早期检测感染是必要的。